About this trial
Perinatal mood and anxiety disorders (PMAD), defined as depression and anxiety during pregnancy or up to 1 year postpartum, account for substantial morbidity and mortality among birthing people globally especially in low- and middle-income countries. Several evidence-based interventions are recommended for identification and management of PMAD by non-specialist providers in resource-limited settings. This cluster-randomized trial seeks to evaluate the effect of a stepped-care intervention for screening and treatment of PMAD among perinatal women, on clinical and implementation outcomes.
Eligibility criteria
Qualifiers
Pregnant and ≥28 weeks gestation
Attending ANC care at the facility
≥14 years old
Screen positive for PMAD symptoms (PHQ-2≥3 and/or GAD-2≥3)
Disqualifiers
Less than 28 weeks gestation
Any woman at high risk of self-harm based on a study self-harm assessment protocol,
Has cognitive impairments or psychotic symptoms
Trial design
Treatments tested in this trial
- Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)
Treatment groups
Sponsors and collaborators
Kenyatta National Hospital
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator